Advancing Cancer Care Reducing  the Risk of Heart  Disease FIGHTING CANCER  Clinical trial  participant Richard Pflaum and  wife Kathy hope he’ll benefit  from advances in treating cancer. Rivaroxaban* is a promising  experimental medicine that  may soon become a new  alternative to warfarin for  reducing the risk of unwanted blood clots.  Johnson & Johnson  Pharmaceutical Research &  Development, LLC (J&JPRD)  recently submitted a New  Drug Application to the U.S.  Food & Drug Administration  (FDA) seeking approval to use rivaroxaban to prevent strokes  in patients with the most  common heart rhythm  disorder—atrial fibrillation.  Results from the ROCKET AF  trial, comparing rivaroxaban  to warfarin, a widely used but  challenging-to-manage drug,  were presented at the  American Heart Association  annual meeting.  The study’s outcome  suggests that “rivaroxaban has  the potential to protect the  2.3 million Americans with atrial  fibrillation from stroke and its devastating complica- tions,” according to Peter M.  DiBattiste, M.D., Vice President  ofCardiovascularDevelopment,  J&JPRD. ROCKET AF is the  seventh successful Phase  III trial in the ongoing rivarox- aban development program. In  2011 , J&JPRD also  expects to learn from the FDA  whether rivaroxaban will be  approved for the prevention of  blood clots following total  knee or total hip replacement  surgeries. disrupt the surrounding tumor  microenvironment that helps  cancer thrive and using  biomarkers to improve patient  outcomes. Abiraterone acetate acts by  blocking the synthesis of  hormones produced by the  body, including those produced  by prostate cancer tissue to fuel  its growth, according to William  Hait, M.D., Ph.D., Global  Therapeutic Area Head,  Oncology. “We believe that  abiraterone acetate is an impor- tant medical advance, and we  look forward to further devel- oping additional therapies for  oncology patients that will help  save the lives of people around  the world,” he says. increase from  2002 .  Abiraterone acetate has not  received marketing authoriza- tion and is for investigational  use only. Based on positive  results from a completed Phase III study, marketing  applications were filed with  regulatory authorities in the  U.S. and Europe in December  2010 , with additional filings  planned for  2011 . With abiraterone acetate, the  oncology franchise is devel- oping strategies it hopes will  one day help prevent or cure  certain types of prostate and  other cancers. Researchers are  working hand-in-hand with  today’s top oncology experts,  testing compounds that “Living with cancer, you need a positive attitude,” says  64 -year-old Richard Pflaum of Bath, England. “What you  need is to be able to take some  sort of action.” So Richard is participating in an ongoing  clinical study with abiraterone  acetate, a promising investigational medicine for the treatment of metastatic  advanced prostate cancer.  Globally, prostate cancer is  the second most frequently  diagnosed cancer in men and  the fifth most common cancer  overall. More than  900,000 new cases of prostate cancer  were diagnosed in  2008 , and  more than  258,000  men died  from the disease, a  16  percent  8  JOHNSON & JOHNSON 2010 ANNUAL REPORT *Rivaroxaban is co-developed with Bayer HealthCare.